FLORENCE, Italy, October 29, 2025 / Biotech Newswire / -- MimeTech S.r.l. today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to its investigational drug Udonitrectag lysine for the treatment of diabetic foot ulcers (DFU).
Existing measures for the treatment of diabetic foot ulcers achieve complete healing in only 30–60% of cases within six months, with 40% one-year recurrence and amputation rates around 20–30% in complicated ulcers. This represents a significant unmet medical need for innovative medicines capable of providing a clinically meaningful and durable improvement in healing and limb salvage.
Evidence from a 6-week, randomised, single-blind, comparative Phase 1/2 study in 24 patients with slow-healing diabetic foot ulcers testing Udonitrectag lysine in addition to standard of care versus standard of care alone suggests that a potentially clinically meaningful treatment effect addressing this unmet medical need can be achieved.
PRIME is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. This voluntary programme is based on enhanced interaction and early dialogue with developers of promising medicines to optimise development plans and accelerate evaluation, helping these medicines reach patients earlier.
“Receiving PRIME designation is an important recognition of the potential of Udonitrectag lysine to make a real difference for patients affected by diabetic foot ulcers,” said Federico Cozzolino, CEO of MimeTech S.r.l. “We look forward to working closely with EMA to advance the development of this innovative therapy and to bring it as soon as possible to patients in need.”
About MimeTech S.r.l.
MimeTech S.r.l. is a biotechnology company based in Florence, Italy, engaged in the development of innovative therapies based on neurotrophin mimetics, primarily proposed for the treatment of dermatologic, neurodegenerative, and cardiovascular diseases, as well as for solid organ transplant.
Contact
MimeTech S.r.l.
Eloisa Perissi
Via della Cernaia 21
I-50129 - Firenze - Italy
+39 3381330372
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Drugs, Investigational; Diabetes Mellitus; Diabetic Foot; Ulcer; Therapies, Investigational; Biotechnology; Amputation, Surgical; Italy; EMA; PRIME designation; MimeTech; Udonitrectag lysine; Diabetic foot ulcers; European Medicines Agency; Wound healing; Limb salvage; Clinical development; Phase 1/2 study; Federico Cozzolino; Neurotrophin mimetics
Source: Biotech Newswire